drugset / Trial / NCT05963347
Go-CHOP as the Frontline Therapy for PTCL
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 2 Study to investigate the safety, tolerability, and anti-tumor activity of golidocitinib in Combination with CHOP as the front-line Treatment for Participants with Peripheral T-cell Lymphomas (PTCL).
Timeline
- Start
- 2023-08-03
- Primary completion
- 2025-07-30
- Completion
- 2026-07-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Golidocitinib | Small molecule | 75 mg | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Prednisone | Other / unclassified | — | — |
| Background | Vincristine | Small molecule | — | — |